Lunai Bioworks (NASDAQ: LNAI) Expands Parkinson's Platform Through Exclusive Tanaist Agreement

Exclusive worldwide agreement adds human cellular validation to Lunai's AI-driven Parkinson's workflow, connecting patient-derived subtypes with disease mechanisms, biomarkers and therapeutic targets SACRAMENTO, Calif. , Sept. 22, 2026 /PRNewswire/ -- Lunai Bioworks, Inc. (Nasdaq: LNAI ), a biology-first AI drug discovery company, today announced an exclusive worldwide license and collaboration agreement with Tanaist, Inc. that adds human cellular phenotyping to Lunai's growing Parkinson's disease discovery and validation platform. The collaboration is designed to connect patient subtypes identified by BioSymetrics, Lunai's wholly owned subsidiary, using its Augusta AI platform with independent patient cohorts and measurable human cellular biology.

Under the agreement, Lunai has exclusive rights to Tanaist's licensed cellular phenotyping technology in the Parkinson's disease field for programs based on Lunai's patient phenoclusters. The companies plan to evaluate whether Lunai's clinical and proteomic signatures can be reproduced across agreed Parkinson's cohorts and connected to measurable differences in human cellular biology. The work is intended to test the robustness and generalizability of the subtype framework and prioritize biomarkers and therapeutic targets for further development. Tanaist's precision-medicine platform combines patient data with dynamic human cellular phenotyping to uncover biological differences that may be difficult to detect through conventional clinical data alone. The scientific approach underlying the platform has been demonstrated in peer-reviewed research published in Nature Genetics and Science Translational Medicine, including work linking human cellular phenotypes to genetic mechanisms, disease biology, and potential therapeutic targets.

The Tanaist collaboration represents the latest step in Lunai's broader Parkinson's strategy, which combines AI-based analysis of longitudinal patient data with complementary experimental validation systems. Together with Lunai's August 2026 collaboration with BrainStorm Therapeutics, the company is building multiple independent paths to test which AI-derived disease signals are reproducible, biologically meaningful and actionable for therapeutic development. Lunai previously analyzed longitudinal clinical information and more than 4,500 proteomic probes from more than 650 participants in the Parkinson's Progression Markers Initiative (PPMI). The analysis identified three clinically distinct Parkinson's subtypes associated with different patterns of disease progression. The next phase of the program will examine whether those findings can be reproduced across additional cohorts and whether the observed clinical and proteomic differences correspond to distinct cellular mechanisms. Establishing that connection is an important step toward determining whether the subtypes can support patient enrichment, biomarker development, and therapeutic target selection.

Advancing From Patient Stratification to Biological Validation The three Parkinson's subtypes identified by Augusta were characterized by fast motor progression, rapid neurological and cognitive decline, and female-enriched functional impairment. The work linked baseline clinical and proteomic characteristics to later disease progression over a median follow-up of approximately 2.5 years, with many partic...